Dr. Dudek is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St SW
Rochester, MN 55905Phone+1 507-284-2511
Summary
- I am board certified in hematology and oncology. I specialize in treatment of lung cancer, mesothelioma, melanoma, pancreatic cancer, and kidney cancer. I lead Early Phase Therapeutic Program for The Cancer Care Center, Regions Hospital, HealthPartners. I am a member of Phase 1 Program at The University of Minnesota.
Education & Training
- Military Medical InstitutePh.D., 1998
- University of MinnesotaFellowship, Hematology and Medical Oncology, 1994 - 1997
- UPMC Medical Education (Harrisburg)Residency, Internal Medicine, 1991 - 1994
- Medical University of WarsawClass of 1989
Certifications & Licensure
- MN State Medical License 1994 - 2025
- IL State Medical License 2012 - 2020
- PA State Medical License 1991 - 2000
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
- Champions of Care Honor Fairview Foundation, 2011
- Outstanding Academic Mentor Award Hematology, Oncology, and Transplantation Fellowship Program, 2010
- Join now to see all
Clinical Trials
- Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors Start of enrollment: 2007 Mar 01
- Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors Start of enrollment: 2005 Nov 01
- Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 61 citationsDurvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.Patrick M. Forde, Valsamo Anagnostou, Z. Sun, Suzanne E. Dahlberg, Hedy L. Kindler
Nature Medicine. 2021-11-08 - 14 citationsLocal irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastases.Pawel Zwolak, Arkadiusz Z. Dudek, Vidya Bodempudi, Julia Nguyen, Robert P. Hebbel
International Journal of Cancer. 2008-02-01 - 24 citationsSU-011248, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor, controls chronic psoriasis.Mani Keshtgarpour, Arkadiusz Z. Dudek
Translational Research. 2007-03-01
Journal Articles
- Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy eraAbern MR1, Scosyrev E, Tsivian M, Messing EM, Polascik TJ, Dudek AZ, Anticancer Res, 5/1/2014
- Radiation recall reaction causing cardiotoxicityMasri SC, Misselt AJ, Dudek A, Konety SH, J Cardiovasc Magn Reson, 4/22/2014
- Phase I Study of Pazopanib and Ixabepilone in Patients With Solid TumorsGanesan C1, Obulareddy SJ, Fischer JH, Antonysamy MA, Jha G, Bliss RL, Dudek AZ, Am J Clin Oncol, 2/26/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- "Melanoma and Glioblastoma Multiforme 2011 ASCO Abstracts"Arkadiusz Dudek, MD, PhD, Best of ASCO Ecuador-2011, Salinas, Ecuador, 7/29/2011
- Monitoring T-cell responses in a phase II study of AGS-003, an autologous dendritic cell-based therapy in patients with newly diagnosed advanced stage renal cell carci...Figlin R. A., Nicolette C. A., Amin A., Dudek A., Logan T., Lance R. S., Holzbeierlein J. M., Pal S. K., Master V. A., DeBenedette M., Tcherepanova I.Y., Jain R., Wil..., J Clin Oncol, 1/1/2011
- Clinical evaluation of food effects on pharmacokinetics of the novel oral taxane, tesetaxel.Danesi H., Dudek A., Spindler E., Alcorn Jr H, J Clin Oncol, 1/1/2011
- Join now to see all
Lectures
- Randomized phase 2 study of maintenance pemetrexed (Pem) versus observation (Obs) for patients (pts) with malignant pleural mesothelioma (MPM) without progression afte...2019 ASCO Annual Meeting - 6/1/2019
- Phase ib and phase II studies of pembrolizumab (P) with bevacizumab (B) for the treatment of metastatic renal cell carcinoma (RCC): BTCRC-GU14-003.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Grand Rounds: "Tailoring Oncology Care with Genomics"Department of Medicine, University of Illinois - 5/28/2013
- Join now to see all
Press Mentions
- Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352February 27th, 2023
- First Test of Anti-Cancer Agent PAC-1 in Human Clinical Trials Shows PromiseDecember 22nd, 2022
- Post-ASCO News Alert: Merck’s KEYNOTE-564 Data Heralds Early Adjuvant Keytruda Use in Renal CancerJune 17th, 2021
- Join now to see all
Grant Support
- Autologous LMI Vaccine For Melanoma And Renal Cell CarcinomaNational Center For Research Resources2004–2006
Professional Memberships
- Member
Other Languages
- Polish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: